γ-globin reactivated autologous hematopoietic stem cells

BIOLOGICAL2 trials

Sponsors

Bioray Laboratories

Conditions

Thalassemia Majorβ Thalassemia Major

Unknown Phase

Safety and Efficacy Evaluation of γ-globin Reactivated Autologous Hematopoietic Stem Cells

CompletedNCT04211480

Bioray Laboratoriesβ Thalassemia Major

Start: 2020-10-01End: 2023-11-27Updated: 2024-01-05

Safety and Efficacy Evaluation of γ-globin Reactivated Autologous Hematopoietic Stem Cells

SuspendedNCT05442346

Bioray LaboratoriesThalassemia Major

Start: 2023-12-25End: 2024-11-30Target: 5Updated: 2024-02-28

Related Papers

Efficacy and Safety of Brl-101, CRISPR-Cas9-Mediated Gene Editing of the BCL11A Enhancer in Transfusion-Dependent β-Thalassemia

Blood2023-11-0211 citations

S271: AN UPDATED FOLLOW-UP OF BRL-101, CRISPR-CAS9-MEDIATED GENE EDITING OF THE BCL11A ENHANCER FOR TRANSFUSION-DEPENDENT BETA-THALASSE

HemaSphere2023-08-013 citations

CRISPR-Cas9-mediated gene editing of the BCL11A enhancer for pediatric β<sup>0</sup>/β<sup>0</sup> transfusion-dependent β-thalassemia.

2022-08-04133 citations